Associate Scientist
Stylus Medicine
Associate Scientist
Stylus Medicine
In vivo genome editing for CAR-T
About Stylus Medicine:
Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company’s approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond.
About the Role:
Stylus Medicine is seeking an intellectually curious and collaborative Associate Scientist to join our analytical development team and aid in the development of characterization techniques for lipid nanoparticles (LNPs) to be used for in vivo delivery of genome engineering material. This role will be responsible for both providing analytical support to the delivery team as well as driving the development of novel analytical techniques. Reporting to the Principal Scientist, LNP Analytics, this individual will play an integral role in advancing transformative in vivo genetic medicines.
Key Responsibilities & Accountabilities:
Qualifications & Skills:
Pay Range: $105,000-$115,000
In vivo genome editing for CAR-T
Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.
Explore more opportunities at Stylus Medicine